Clinical trials: NSCLC (non-small Cell Lung Cancer)
Non-small Cell Lung Cancer
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement [N2])…
- Trial name
- INTerpath-002 (NCT06077760)
- Testing
- Intismeran autogene, Pembrolizumab
- Where
- 229 sites in United States, Argentina and 31 more
- Volunteers
- 868 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1<10%
Nivolumab is now the standard of care for second-line treatment of advanced squamous or nonsquamous NSCLC regardless of the tumor's expression of PD-1L.
- Trial name
- NCT03808480
- Testing
- CA and Nivolumab
- Where
- South Korea
- Volunteers
- 22 people
- Sponsor
- National Cancer Center, Korea
Lung Cancer, Non Small Cell Lung Cancer
The Development, Safety, and Feasibility of an Artificial Intelligence-Powered Platform (NodeAI) for Real-Time Prediction of Mediastinal Lymph Node Malignancy During Endobronchial Ultrasound Staging for Lung Cancer
Lung cancer is the leading cause of annual cancer deaths globally, more than breast, prostate, and colon cancers combined. The staging of chest lymph nodes (LNs) is a crucial step in the lung cancer diagnostic pathway because it…
- Trial name
- NodeAI (NCT06540196)
- Testing
- NodeAI, Surgeon
- Where
- Canada
- Volunteers
- 600 people
- Sponsor
- McMaster University
Non Small Cell Lung Cancer
A Study Evaluating the Effect of Aumolertinib on the Pharmacokinetics of Midazolam in Patients With NSCLC
This is an open-label, fixed-sequence Phase I clinical study that evaluates the effect of multiple doses of aumolertinib on the pharmacokinetics of midazolam (CYP 3A4 probe substrate) in sensitive EGFR (Epidermal Growth Factor…
- Trial name
- NCT06926413
- Testing
- Aumolertinib；midazolam
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non Small Cell Lung Cancer
Image Mining and ctDNA to Improve Risk Stratification and Outcome Prediction in NSCLC Applying Artificial Intelligence.
Lung cancer is the leading cause of cancer-related death in Europe. Pathological staging is the gold standard, but it can be influenced by neo-adjuvant treatment and number of sampled lymph nodes; it is not feasible in advanced…
- Trial name
- NCT06163846
- Testing
- Assess the role of baseline image mining, ctDNA data and their combination in patient staging and risk stratification
- Where
- Italy
- Volunteers
- 415 people
- Sponsor
- IRCCS San Raffaele
Lung Neoplasms
A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 Given In Combination With Chemotherapy
The purpose of this study is to determine whether CP-547,632, an oral VEGFR-2 tyrosine kinase inhibitor when given in combination with chemotherapy (carboplatin and paclitaxel) is effective in the treatment of advanced stage…
- Trial name
- NCT00074854
- Testing
- CP-547,632
- Where
- 20 sites in United States
- Volunteers
- 87 people
- Sponsor
- Pfizer
Lung Cancer
Gefitinib and Sirolimus in Treating Patients With Recurrent or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as sirolimus, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00098462
- Testing
- gefitinib, sirolimus
- Sponsor
- Jonsson Comprehensive Cancer Center
Mesothelin-expressing Advanced Cancers
A Study of ZW171 in Participants With Advanced or Metastatic Mesothelin-expressing Cancers
This study is being done to find out if ZW171 is safe and can treat participants with advanced (locally advanced [inoperable] and/or metastatic) mesothelin-expressing cancers.
- Trial name
- NCT06523803
- Testing
- ZW171
- Where
- 15 sites in United States, Germany and 2 more
- Volunteers
- 32 people
- Sponsor
- Zymeworks BC Inc.
Carcinoma, Non Small Cell Lung
Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer
The purpose of this study is to evaluate the efficacy of vorinostat and bortezomib in the third line treatment of advanced NSCLC, as well as to assess toxicity (including neuropathy) and tolerability of this regimen.
- Trial name
- NCT00798720
- Testing
- vorinostat, bortezomib
- Volunteers
- 18 people
- Sponsor
- University of Wisconsin, Madison
Non Small Cell Lung Cancer
Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours
A Phase II, Open Label, Single-arm Study to Assess the Safety and Efficacy of AZD9291 in Patients with Locally Advanced/Metastatic Non Small Cell Lung Cancer whose Disease has Progressed with Previous Epidermal Growth Factor…
- Trial name
- AURA2 (NCT02094261)
- Testing
- AZD9291
- Where
- 44 sites in United States, Canada and 6 more
- Volunteers
- 210 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer Stage I
Adjuvant Chemotherapy for High-Risk Pathologic Stage I Non-Squamous NSCLC
Brief Summary The goal of this clinical trial is to evaluate the effect of postoperative adjuvant chemotherapy (ACT) in patients with stage I non-squamous non-small cell lung cancer (NSCLC) after curative resection.
- Trial name
- NCT07250360
- Testing
- Adjuvant chemotheapy
- Volunteers
- 2,072 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation
Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
This phase II Lung-MAP trial studies how well rucaparib works in treating patients with genomic loss of heterozygosity (LOH) high and/or deleterious BRCA1/2 mutation stage IV non-small cell lung cancer or that has come back.
- Conditions
- Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Loss of Heterozygosity, Lung Non-Small Cell Squamous Carcinoma
- Trial name
- NCT03845296
- Testing
- Rucaparib
- Where
- 950 sites in United States
- Volunteers
- 64 people
- Sponsor
- SWOG Cancer Research Network
Non-Squamous Non-Small Cell Lung Cancer
A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation
This multicenter, randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of onartuzumab in combination with erlotinib in patients with previously untreated, unresectable stage IIIB or IV…
- Trial name
- NCT01887886
- Testing
- erlotinib, onartuzumab
- Where
- 35 sites in United States, France and 6 more
- Volunteers
- 10 people
- Sponsor
- Hoffmann-La Roche
Non-Small Cell Lung Cancer
Study Using WST11 in Patients With Obstructing Endobronchial Non-Small Cell Lung Cancer
The aim of this study is to determine the dose of WST11 and light energy necessary to obtain desobstruction of the bronchial lumen using Vascular Targeted Photodynamic therapy in obstructive Non-Small Cell Lung Cancer.
- Trial name
- NCT00974662
- Testing
- WST11
- Where
- France
- Volunteers
- 3 people
- Sponsor
- Steba Biotech S.A.
Colorectal Cancer, Non-small Cell Lung Cancer
Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib
This is a Phase 1 open-label, dose-escalation trial using "3+3" design, evaluating MM-151 co-administration with MM-121, MM-141, and trametinib at varying dose levels.
- Conditions
- Colorectal Cancer, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT02538627
- Testing
- MM-151, MM-121, MM-141
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- Merrimack Pharmaceuticals
Lung, Lung Adenocarcinoma
Reinforced and Non-Reinforced Staple Lines in Fissureless Lobectomy
Prolonged Air Leak (PAL) is a common and serious problem after lung surgery. It can lead to worse patient outcomes, longer hospital stays, and higher costs.
- Conditions
- Lung, Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Cancer, Non-Small Cell
- Trial name
- NCT06602661
- Testing
- Fissureless Lobectomy with Reinforced Staple Lines, Fissureless Lobectomy with Non-Reinforced Staple Lines
- Where
- Canada
- Volunteers
- 65 people
- Sponsor
- Surrey Thoracic Surgery Group
Lung Cancer, Relapse/Recurrence
Combined Relapse Prediction Model for Resectable Non-Small Cell Patients - a Prospective Clinical Feasibility Trial
For patients with lung cancer who have undergone tumor resection, early relapse significantly impacts survival. However, there are currently no reliable screening or imaging tools available to identify patients at risk of early…
- Trial name
- NCT06262386
- Testing
- Cisplatin based chemottherapy
- Where
- Taiwan
- Volunteers
- 358 people
- Sponsor
- Chang Gung Memorial Hospital
Drug Toxicity, Lung Cancer
13-Cis Retinoic Acid With or Without Vitamin E for Prevention of Lung Cancer
RATIONALE: 13 Cis retinoic acid may prevent the development of cancer cells. PURPOSE: Randomized double-blinded phase II trial to study the effectiveness of 13-cis retinoic acid with or without vitamin E for chemoprevention or…
- Trial name
- 13-Cis (NCT00002586)
- Testing
- 13-cis retinoic acid, Tocopherol
- Where
- 4 sites in United States
- Volunteers
- 96 people
- Sponsor
- University of Colorado, Denver
Lung Cancer
Cisplatin and Docetaxel With or Without Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Newly Diagnosed Stage III Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00113386
- Testing
- filgrastim, pegfilgrastim, cisplatin
- Where
- 76 sites in United States
- Volunteers
- 19 people
- Sponsor
- Radiation Therapy Oncology Group
Malignant Pleural Effusion, Recurrent Non-small Cell Lung Cancer
Imatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
This phase II trial is studying how well giving imatinib mesylate together with paclitaxel works in treating older patients with stage IIIB or stage IV non-small cell lung cancer.
- Conditions
- Malignant Pleural Effusion, Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00408460
- Testing
- imatinib mesylate, paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- University of Washington
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.